BUSINESS

• Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
  February 8, 2021

• AstraZeneca Files COVID-19 Vaccine in Japan
  February 5, 2021

• MSD to Launch Silgard 9 on Feb. 24, but Mass Supply in Japan Unlikely Until 2023
  February 5, 2021

• Gilead Mulling Japan Entry into PIII Study for Inhaled Version of Veklury
  February 5, 2021

• Kyowa Kirin’s 2020 Sales Rise 4.1% on Growth of 3 Strategic Products
  February 5, 2021

• Chugai Closes Book with Double-Digit Earnings Growth on Overseas Sales, Royalties
  February 5, 2021

• Takeda’s 9-Month Sales Skid 3.6% on Dips in Rare Diseases, Neuroscience
  February 5, 2021

• PI/IIa Study for AnGes’ Hypertension Vaccine Confirms Antibody Production
  February 5, 2021

• Otsuka Teams Up with US Firm on Development of Gene Testing Kit for Blood Cancers
  February 5, 2021

• Daiichi Sankyo Kicks Off Global PII of ADC Patritumab for EGFR-Mutated NSCLC
  February 5, 2021

• Kaken to Copromote Mochida’s Forteo Follow-On from April
  February 5, 2021

• Drug Makers Moving to Discontinue Ranitidine/Nizatidine Products over Carcinogen Issue
  February 4, 2021

• Daiichi Sankyo Commences PI of ADC DS-6000 in US
  February 4, 2021

• Eisai’s April-December Profits Slip on Aggressive Investments
  February 4, 2021

• US FDA Accepts NDA for Santen/Ube's Glaucoma Drug
  February 4, 2021

• Eisai Neurology Chief Says Partners Continue to Stand Behind Aducanumab
  February 4, 2021

• Mitsubishi Tanabe’s April-December Sales Down 2.4% over Price Cuts, Generic Erosion
  February 4, 2021

• Mitsubishi Tanabe’s Dyskinesia Med Smashes Goal in Japan PII/III, Eyes Submission in FY2021
  February 4, 2021

• Ono Earns Japan, Asia Rights to Ribon’s PARP7 Inhibitor
  February 3, 2021

• Internal Probe Finds No Physical Evidence, Testimony in Ex-Sandoz Rep’s Residual Drug Resale Case
  February 3, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 246
• 247
• 248
• 249
• 250
• 251
• 252
• 253
• 254
• …
• Next ›
• 最終 »